2023
Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.
Rahman S, Long J, Westvold S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy. JCO Oncology Practice 2023, 19: 28-28. DOI: 10.1200/op.2023.19.11_suppl.28.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsInitial treatmentRetrospective cohort studyUse of immunotherapyYear of diagnosisRenal cell carcinomaDirect treatment costsMean Medicare paymentsMedicare paymentsMedicare Part DInitial therapyCohort studyMetastatic diagnosisCell carcinomaCombination therapyImmunotherapyMedicare beneficiariesPatientsAge 65Disease controlOlder ageStudy periodTherapyDiagnosis
2012
Anemia and functional disability in older adults with cancer.
Owusu C, Tew W, Hardt M, Mohile S, Klepin H, Gross C, Gajra A, Lichtman S, Ramani R, Katheria V, Zavala L, Hurria A. Anemia and functional disability in older adults with cancer. Journal Of Clinical Oncology 2012, 30: 9109-9109. DOI: 10.1200/jco.2012.30.15_suppl.9109.Peer-Reviewed Original ResearchFunctional disabilityProspective studyOlder adultsMulti-center prospective studyUnintentional weight lossCorrection of anemiaRandomized-controlled trialPre-treatment variablesOlder ptsChemotherapy toxicityGeriatric assessmentPatient agePrimary outcomeMean HbFunctional statusInstrumental activitiesDaily livingAnemiaAdvanced stageMultivariate analysisAge 65Secondary analysisModifiable strategiesBivariate analysisLogistic regressionPredictors of early discontinuation of chemotherapy (EDC) in patients (pts) age 65 or older with stage IV non-small cell lung cancer (NSCLC).
Gajra A, Tew W, Hardt M, Mohile S, Owusu C, Klepin H, Gross C, Lichtman S, Katheria V, Hurria A. Predictors of early discontinuation of chemotherapy (EDC) in patients (pts) age 65 or older with stage IV non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2012, 30: e18133-e18133. DOI: 10.1200/jco.2012.30.15_suppl.e18133.Peer-Reviewed Original ResearchStage IV non-small cell lung cancerNon-small cell lung cancerPoor physical functionOlder ptsPhysical functionAge 65Multi-site prospective studyBivariate analysisGeriatric assessment variablesPatients age 65Cell lung cancerMultivariate logistic regressionLower mean HbPt ageChemotherapy toxicityEarly discontinuationAlbumin levelsMean HbProspective studyPoor outcomeHigher cancerLung cancerPhysical scoresSubset analysisDisease progression
2011
Predictors of primary dose reduction (PDR) among patients (pts) age 65 and older receiving adjuvant chemotherapy (chemo).
Klepin H, Gajra A, Hardt M, Tew W, Mohile S, Owusu C, Gross C, Lichtman S, Ramani R, Katheria V, Brown J, Jayani R, Hansen K, Togawa K, Klapper S, Wong F, Hurria A. Predictors of primary dose reduction (PDR) among patients (pts) age 65 and older receiving adjuvant chemotherapy (chemo). Journal Of Clinical Oncology 2011, 29: 9003-9003. DOI: 10.1200/jco.2011.29.15_suppl.9003.Peer-Reviewed Original ResearchPrimary dose reduction (PDR) of chemotherapy (chemo) in patients (Pts) older than age 65 with advanced cancer (Ca) and toxicity outcomes.
Gajra A, Hardt M, Tew W, Mohile S, Owusu C, Klepin H, Gross C, Lichtman S, Ramani R, Brown J, Katheria V, Jayani R, Hansen K, Togawa K, Klapper S, Hurria A. Primary dose reduction (PDR) of chemotherapy (chemo) in patients (Pts) older than age 65 with advanced cancer (Ca) and toxicity outcomes. Journal Of Clinical Oncology 2011, 29: 9037-9037. DOI: 10.1200/jco.2011.29.15_suppl.9037.Peer-Reviewed Original Research